Education
About Us
Working with TipRanks
Follow Us
Tissue Regenix Group PLC (GB:TRX)
LSE:TRX
Total Valuation
Tissue Regenix has a market cap or net worth of £25.93M. The enterprise value is 51.23M.
Market Cap£25.93M
Enterprise Value51.23M
Share Statistics
Tissue Regenix has 71,395,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding71,395,640
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Tissue Regenix’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee359.67K
Profits Per Employee-20.35K
Employee Count82
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Tissue Regenix is ―. Tissue Regenix’s PEG ratio is ―.
PE Ratio―
PS Ratio1.05
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Tissue Regenix had revenue of 29.49M and earned -1.71M in profits. Earnings per share was -0.02.
Revenue29.49M
Gross Profit14.04M
Operating Income-394.00K
Pretax Income-1.34M
Net Income-1.71M
EBITDA446.00K
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was 386.95K and capital expenditures -511.36K, giving a free cash flow of -124.42K billion.
Operating Cash Flow386.95K
Free Cash Flow-124.42K
Free Cash Flow per Share>-0.01
Dividends & Yields
Tissue Regenix pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.28
52-Week Price Change-43.41%
50-Day Moving Average41.22
200-Day Moving Average55.33
Relative Strength Index (RSI)28.78
Average Volume (3m)34.06K
Important Dates
Tissue Regenix upcoming earnings date is Jun 5, 2025, TBA Not Confirmed.
Last Earnings DateSep 10, 2024
Next Earnings DateJun 5, 2025
Ex-Dividend Date―
Financial Position
Tissue Regenix as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Tissue Regenix has paid -12.00K in taxes.
Income Tax-12.00K
Effective Tax Rate―
Enterprise Valuation
Tissue Regenix EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Tissue Regenix has £4.65M in cash and marketable securities with $0.00 in debt, giving a net cash position of £4.75M billion.
Cash & Marketable Securities£4.65M
Total Debt$0.00
Net Cash£4.75M
Net Cash Per Share£0.07
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Tissue Regenix is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―